NEWS , Press release 2023.4.24 Alliance between Noile-Immune Biotech, Inc. and Rebirthel Co., Ltd. on PRIME allogeneic CAR-T Cell Therapy using Immune Cells induced from Pluripotent Stem Cells

Rebirthel and Noile-Immune Biotech announce that they have entered into a contract on collaborative research and commercialization of next-generation gene-modified immune cell therapy combining Rebirthel’s technology for producing immune cells from pluripotent stem cells and Noile-Immune’s PRIME (Proliferation-inducing and migration- enhancing) technology for adapting immune cell therapies such as those of CAR-T cells and TCR-T cells to solid cancer.

For details, please refer to the attached press release.